SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001723128-24-000003
Filing Date
2024-01-10
Accepted
2024-01-10 07:03:53
Documents
12
Period of Report
2024-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20240110.htm   iXBRL 8-K 38549
  Complete submission text file 0001723128-24-000003.txt   168516

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20240110.xsd EX-101.SCH 1995
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20240110_lab.xml EX-101.LAB 24139
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20240110_pre.xml EX-101.PRE 12599
6 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20240110_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 24524849
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)